Zhejiang Cancer Hospital
Zhejiang, China
NCT Number: NCT06873997
By analyzing the clinical data of patients with advanced breast cancer with bone metastasis admitted to our center from January 1, 2021 to February 28, 2023, this study aims to understand the real-world clinical diagnosis and treatment of breast cancer with bone metastasis, including the epidemiology of bone metastasis, screening and diagnosis methods, selection of clinical treatment methods, and occurrence of SRE. To explore the risk factors related to bone metastasis-free survival (BMFI). In addition, we will explore the use of quantitative analysis of CT values to evaluate bone metastases of breast cancer, aiming to provide a new method for imaging quantitative efficacy evaluation of bone metastases.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Zhejiang, China
The specific contents of our research include the basic information of breast cancer patients with bone metastasis in the early stage, neoadjuvant therapy, surgery and postoperative pathology, and adjuvant therapy; The time and location of recurrence and metastasis, treatment plan, and information related to bone metastasis include time, location, diagnosis method, treatment, occurrence of SRE, and changes in CT values of bone lesions before and after drug treatment. The objective is to understand the risk factors of bone metastasis-free survival (BMFI) of breast cancer patients with bone metastases in the real world, provide evidence and data for clinical accurate screening, observe the CT value changes of bone lesions through imaging (CT quantitative), and explore a new method for evaluating the efficacy of bone metastases.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Exclusion is defined as meeting 1 of the following exclusion criteria:
Time frame: From the diagnosis of breast cancer to the occurrence of bone metastasis,assessed up to 100 months
Bone metastasis-free interval (BMFI) is the time between diagnosis of breast cancer and the onset of bone metastases
Time frame: From the diagnosis of breast cancer to the conclusion of the study period,assessed up to 100 months
Clinical characteristics of patients with bone metastasis include age, menstrual status, body mass index (BMI), presence or non-presence of underlying disease, tumor location, primary tumor size, number of lymph node metastases, TNM stage, pathologic type, histological classification, vascular thrombus invasion, estrogen receptor (ER) status, progesterone receptor (PR) status, and other factors. Human epidermal growth factor receptor-2 (HER-2) expression, Ki-67 level, whether chemotherapy and radiotherapy, recurrence and metastasis time, recurrence and metastasis site.
Time frame: From the start of treatment with bone care drugs to 1 year
CT value selection method: A professional physician manually selected a region of interest (ROI) for a single bone metastatic lesion, and recorded the mean value of CT value, which was expressed in Hounsfield units (HU). The ROI difference of the same bone metastasis before and after treatment was not more than ±10mm2
Time frame: rom the diagnosis of breast cancer to the occurrence of bone metastasis,assessed up to 100 months
The time of bone metastasis were included
Time frame: From the diagnosis of breast cancer to the occurrence of bone-related events,assessed up to 100 months.
Skeleton-relative Events (SREs) include pathological fractures, spinal cord compression, bone surgery, and radiation therapy
Zhejiang Cancer Hospital
Other
Analysis of the Occurrence Time of Bone Metastasis and Disease Treatment Patterns in Patients with Breast Cancer Bone Metastasis: a Retrospective Study from China
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03328026
Breast Cancer, Breast Cancer Metastatic
Newport Beach, California, United States
View Trial DetailsNCT02000622
BRCA 1 Gene Mutation, BRCA 2 Gene Mutation
San Diego, California, United States
View Trial DetailsNCT04603183
Breast Cancer Metastatic
Milan, Italy
View Trial DetailsNCT03328884
Breast Cancer Metastatic
Badalona, Spain
View Trial Details